Scynexis (SCYX) FCF Margin (2013 - 2026)
Scynexis' (SCYX) quarterly FCF Margin came in at 6334.04% in Q2 2026, down 578456.0% on a YoY basis from N/an in Q2 2025, and down 6518.38% quarter-over-quarter from 98.69% in Q4 2025.
Powered by 
Analysis
Scynexis (SCYX) FCF Margin (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported FCF Margin for 13 consecutive years, with 6334.04% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 578456.0% year-over-year to 6334.04%; the trailing twelve-month figure through Jun 2026 stood at 69.26% (up 67052.0% YoY), and the FY2025 full-year result was 25.64%, up 61528.0% from the prior year.
- FCF Margin slipped to 6334.04% in Q2 2026 per SCYX's latest filing, from 98.69% in the prior quarter.
- Across five years, FCF Margin topped out at 705.22% in Q3 2023 and bottomed at 6334.04% in Q2 2026.
- Historically, FCF Margin has averaged 1331.98% across 5 years, with a median of 1404.46% in 2022.
- The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 269818 bps in 2022, then sank 578456 bps in 2026.
- Over 5 years, FCF Margin stood at 1496.46% in 2022, then surged by 91 bps to 133.43% in 2023, then tumbled by 660 bps to 1014.02% in 2024, then soared by 110 bps to 98.69% in 2025, then sank by 6518 bps to 6334.04% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 6334.04%, 98.69%, and 2611.98% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -6,334.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,334.04% |
| Dec 31, 2025 | 98.69% |
| Sep 30, 2025 | -2,611.98% |
| Jun 30, 2025 | -549.49% |
| Mar 31, 2025 | -2,904.67% |
| Dec 31, 2024 | -1,014.02% |
| Sep 30, 2024 | 115.91% |
| Jun 30, 2024 | -1,475.54% |
| Mar 31, 2024 | -291.84% |
| Dec 31, 2023 | -133.43% |
| Sep 30, 2023 | 705.22% |
| Jun 30, 2023 | 56.60% |
| Mar 31, 2023 | -1,674.60% |
| Dec 31, 2022 | -1,496.46% |
| Sep 30, 2022 | -1,445.60% |
| Jun 30, 2022 | -1,404.46% |
| Mar 31, 2022 | -2,284.00% |
| Dec 31, 2021 | -4,194.64% |
| Sep 30, 2021 | -3,259.88% |
| Mar 31, 2021 | -7.78% |